

miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men

Clayton Yates¹, Mark D. Long², Moray J. Campbell², Lara Sucheston-Campbell³

¹Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088,

²Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, ³Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263

TABLE OF CONTENTS

1. Abstract
2. Genetic and epigenetic drivers of PCa are intertwined
3. MicroRNA act as epigenetic drivers of PCA
4. Exploiting serum expression of miRNA to predict PCa
5. Translocation of the TMPRSS2 gene associate with aggressive disease but differ in their incidence across races
6. Are miRNA race-specific, epigenetic drivers for TMPRSS2 fusion-negative PCa?
7. An analytical pipeline to examine changes in miRNA in TMPRSS2-fusion negative PCa
8. Downstream targets of key miRNA
9. Perspective
10. Acknowledgements
11. References

1. ABSTRACT

African Americans (AAs) who have PCa typically have more aggressive disease and make up a disproportionate number of the disease deaths, relative to European Americans (EAs). TMPRSS2 translocations, a common event in EA patients, are exploited in diagnostic and prognostic settings, whereas they are diminished in frequency in AA men. Thus, these patients with TMPRSS2 fusion-negative disease represent an under-investigated patient group. We propose that epigenetic events are a significant and alternative driver of aggressive disease in fusion-negative PCa. To reveal epigenetically governed microRNAs (miRNAs) that are enriched in fusion-negative disease and associated with aggressive in AA PCa, we leveraged both our experimental evidence and publically available data. These analyses identified 18 miRNAs that are differentially altered in fusion-negative disease, associated with DNA CpG methylation, and implicated in aggressive and AAPCAs. Understanding the relationships between miRNA expression, upstream epigenetic regulation by DNA methylation, and downstream regulation of mRNA targets in fusion negative disease is imperative to understanding the biological basis of the racial health disparity in PCa.

2. GENETIC AND EPIGENETIC DRIVERS OF PROSTATE CANCER (PCa) ARE INTERTWINED

Amongst men in the US, PCa is most common non-cutaneous cancer diagnosed and second leading

cause of death (1, 2). This cancer is heterogeneous in terms of progression rates, and various genetic and epigenetic alterations are prevalent and appear to be factors in the tumorigenesis and progression of PCa.

Currently, in PCa, the clinical parameters do not accurately predict progression risks to more aggressive stages of disease. For example, the parameters used for assigning men to radical prostatectomy (PSA level, TNM stage and Gleason score) lack the specificity and sensitivity to distinguish accurately men who both need and will be cured by this treatment, from those who will experience treatment failure typified with rising PSA following surgery (so-called biochemical failure) (3, 4). This is of clinical significance, as patients who experience treatment failure are more likely to progress to more aggressive forms of PCa with increased risks of tumor-related mortality (5, 6). Furthermore, compounding these uncertainties are issues concerning the sensitivity and specificity of the PSA test itself (4). The result of this ambiguity is that men who do not require therapy are treated with either radical surgery or high-dose radiation because their physicians are unable to tell who “needs” therapy (1, 2). Thus, identifying and characterizing non-invasive biomarkers to identify those men who need more aggressive treatment are required.

This ambiguity is further obscured because the incidence and natural history of PCa varies between races. American men of African ancestry have a 19%

higher incidence and 37% higher mortality from PCa compared to men of European ancestry (reviewed in (7-10)). Thus, in African American (AA) PCa patients, the disease appears more aggressive and occurs at a younger age, than in European American (EA) patients.

In an effort to define the disease, multiple groups, including the Cancer Genome Atlas (TCGA) consortium, have added to previous understanding (11, 12) and have established roles for common genetic alterations in PCa (13-15) and novel somatic mutations, including Mediator of RNA Polymerase II Transcription, Subunit 12 (MED12), Forkhead Box A1 (FOXA1), and Speckle-Type POZ Protein (SPOP). The E3 ubiquitin ligase adaptor, SPOP, shows recurrent mutations in 6-15% of tumors across multiple independent cohorts (14, 16). Also supporting the importance of androgen receptor (AR) signaling in PCa and the cross-talk with epigenetic events, the coactivator Nuclear Receptor Coactivator 2 (NCOA2) is commonly amplified (15, 17). Furthermore, mapping of copy number variations re-enforces the significance of PTEN loss and MYC gain (18). Recently, genetic changes have been used to map clonal evolution of metastatic PCa tumors and have revealed the possibility of multi-cancer clonal evolution within a single tumor (19, 20).

The complex nature of cancer phenotypes, however, cannot be explained by genetic components alone (21). Epigenomic modifications and events contribute to cell transformation. These events can be defined as heritable changes to the expression and regulation of gene expression that are not associated with alteration in the DNA sequences (22), although of course deregulated epigenetic events are often downstream of genetic changes (23, 24).

Epigenomic events include the control of chromatin structure and the function of non-coding RNAs, including microRNA (miRNA). Chromatin structure, which is dynamically regulated and generates a highly plastic interface between transcription factors and the genome, governs gene expression. Similarly, non-coding RNA species affect both chromatin structure and transcriptional responses and regulate transcriptional networks. Therefore, these events impact many aspects of cell signaling and function (reviewed in (25)). In turn, chromatin structure is regulated by hundreds of proteins, often acting in large complexes, that initiate local and large-scale control of the position of nucleosomes and the post-translational modifications to the histones contained within nucleosomes (26-29) (reviewed in (30)). These actions also integrate with other complexes that govern the status of DNA CpG methylation. In this manner, the epigenome regulates the transcriptional control of gene networks related to cell proliferation, differentiation, and programmed death.

Epigenomic events appear to play distinct yet complementary roles to genomic events and add to an explanation for the basis of cancer, for many cancers show gene-specific and global changes in DNA CpG methylation and/or altered histone modification patterns (30-34). For example, up-regulation of the histone methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), appears commonly in both localized and metastatic PCas and associates with a poorer prognosis (35, 36). These histone modifications govern tissue-specific gene regulation and are often intertwined with the actions of DNA methyltransferases (DNMTs) (37) to bring about stable and heritable changes in the capacity (both positive and negative) for regulation of gene expression.

3. MICRORNA ACT AS EPIGENETIC DRIVERS OF PCa

In parallel to the well-established understanding on the role of classical epigenetic events, the role of non-coding RNA in epigenetic regulation of gene expression has also emerged. The four types of small RNAs, namely, small nuclear (sn)RNAs, small nucleolar (sno)RNAs, miRNAs, and transfer (t)RNAs, correspond to as much as 85% of total small annotated RNAs as determined by GENCODE. Similarly, ENCODE data reveals the wide range expression of miRNAs in different normal and cancer cell lines (38), supporting the concept that miRNAs are components of gene regulation networks and are expressed differentially in disease stages. Although miRNAs represent only ~1% of the genome, they are estimated to target 30% of the genes (39). Furthermore, there is de-regulation of miRNAs for a variety of solid tumors, including breast cancers, colon cancers, and PCas (40-44).

In PCa, several miRNAs are differentially regulated and act as both tumor suppressors and onco-miRs. For instance, miR-221 and miR-222 are upregulated in castration-resistant PCa cells (45) and appear to control cyclin-dependent kinase (Cdk) inhibitors p27^{KIP1} and p57^{KIP2}, and thus the cell cycle (46, 47), PI3K and PTEN signaling (48), and a range of other signaling events (49-53), although some contradictory findings suggest that the subtleties of miRNA function are not yet fully revealed (54).

Similarly, miR-125b and miR-143 are upregulated in serum samples from patients with metastatic PCa as compared to those from normal individuals (55). Expression of miR-125b in serum of PCa patients is reported to be upregulated as compared to normal controls (56); other studies report it to be downregulated in PCa as compared to normal or benign prostatic hyperplastic samples (57-59). miR-125b regulates cell proliferation in PCa cell lines (60), and is suggested to be upregulated by androgen signaling (61). Functionally, in PCa, miR-125b targets BAK1 (61)

(a pro-apoptotic member of the BCL-2 gene family) and EIF4EBP1 (Eukaryotic translation initiation factor 4E-binding protein 1), a gene that encodes a member of a family of translation repressor proteins (58).

Other miRNAs have been identified as tumor suppressors, including miR-143, miR-145, and the miR-200 family. Expression of miR-143 and miR-145 are suppressed in PCas and negatively associate with metastasis (62). These miRs contribute to PCa progression through the epithelial-mesenchymal transition (EMT) (62) and loss of their repressive effect on the EGFR/RAS/MAPK pathway (62). miR-205 and miR-200 family miRNAs, also downregulated in PCas, regulate the EMT by targeting ZEB1 and ZEB2 in PCas (50, 63, 64).

4. EXPLOITING SERUM EXPRESSION OF miRNA TO PREDICT PCa

Understanding and exploiting serum miRNA classifiers in PCa patients offers an alternative route to accurate diagnosis of disease. Mandel and Metais first identified serum-borne nucleic acids in 1948; of these, miRNAs potentially hold the greatest diagnostic promise (reviewed in (65)). miRNAs appear to contribute to multiple oncogenic actions in PCas (reviewed in (58)). They are secreted into serum, where they remain stable (66-69) and can be reliably extracted and measured (56, 70-72). Using serum-borne molecules as prognostic markers is attractive for several reasons. First, they can overcome the limitations of inaccurate sampling of the prostate gland for the presence of cancer. Second, they can encapsulate the effects of heterotypic cell interactions within the tumor micro-environment. Third, they can be used as a non-invasive test procedure and, therefore, hold considerable promise to be exploited as accurate and functional prognostic markers of PCa. Reflecting this potential, studies have now established that miRNA expression can identify PCa that is at an advanced stage and distinguish it from less aggressive or indolent states, and tumors that have the potential to become invasive from non-invasive, organ-confined tumors (56-58, 73-77).

Expression of miRNAs is frequently disrupted in malignancies (reviewed in (42)), and epigenetic inactivation via promoter CpG island hypermethylation is commonly observed for miRNAs with putative growth-inhibitory functions (reviewed in (78)). For example, in PCa, promoter hypermethylation is associated with loss of miR-200 family members that regulate the EMT and cell migration/invasion. Similarly, hypermethylation of the promoter of miR-34a prevents its regulation by p53 and thereby distorts apoptosis and other functions (79-82). However, to date, most studies have focused on DNA methylation and miRNA interactions in general without asking if these alterations differ in either specific subgroups or racial populations.

These functional relationships and mechanisms of disruption suggest that miRNAs can be exploited to reveal the basis for fusion-negative PCas. Furthermore, miRNAs hold considerable promise to be exploited as accurate and functional prognostic serum markers of PCa (83-87) because they can encapsulate events within the tumor micro-environment and overcome the limitations of inaccurate tumor sampling at biopsy. From a biostatistical perspective, given that there are fewer miRNAs than mRNAs, genome-wide coverage is more readily achieved, and the statistical penalties typically associated with mRNA genome-wide testing can be avoided (88).

5. TRANSLOCATIONS OF THE TMPRSS2 GENE ASSOCIATE WITH AGGRESSIVE DISEASE BUT DIFFER IN THEIR INCIDENCE ACROSS RACES

To identify men with aggressive cancer, Chinnaiyan and colleagues pioneered approaches for identifying and exploiting translocations across the genome in PCa (89-94). This group identified common, and unsuspected, translocations of the TMPRSS2 gene and the ETS-Related Gene (ERG), which is part of the ETS transcription factor family that has oncogenic functions. The TMPRSS2 gene codes for an androgen-responsive protease specific to prostate cells, whose expression and genetic variation is associated with aggressive PCa (95, 96). Therefore, this fusion leads to overexpression of ERG, which in turn regulates multiple genes, including AR-responsive genes (91) (reviewed (97)). Following this discovery (94), and as a result of these pivotal studies, much attention has been given to the TMPRSS2-ERG and related ETS family translocations as potential biomarkers, with over 600 publications following. These gene translocations are common and are related to disease stage and progression risks (98-101). There is therefore good evidence that they act as an androgen-activated tumor driver, justifying clinical exploitation; however, the biological and clinical significance of this event remains an active research area (102-108). As a result, there have been efforts to exploit detection of these translocation products in urine. The goal of these studies has been to generate a clinically approved, urine-based approach to aid in early detection, in the so-called Mi-Prostate Score (89).

This clinical development depends on frequency of the translocation products in the patient population. The TMPRSS2-ERG translocation (94) is commonly and consistently identified in approximately 50% of EAs. This focus has to some extent overlooked the fact that the prevalence of these fusion products is lower for other ethnicities including AA, Japanese, and Chinese patients (109). The rate of TMPRSS2-ERG translocations in AA men appears to be significantly lower, in the range of 10-30% (110-113). AA patients, in addition to having

lower incidence of TMPRSS2:ERG fusion, also have lower expression of ERG protein (109, 114, 115). For example, in matched cohorts of 91 AA and 91 EA men, there was lower expression of ERG in AA vs EA index tumors (29% vs 63%) (116). This was more pronounced for higher-grade cancers, in which nearly 60% of EA patients were ERG-positive, whereas only 10% of AA patients were ERG-positive (117, 118). Reflecting this discrepancy, the Mi-Prostate Score test is more accurate for EA than AA patients (119). A follow-up publication to these findings found that, in 154 AA men compared to 243 EA men, AA men are more likely to be negative for many common translocations including: ERG-negative, ETS-negative, SPINK1-negative disease (51% v 35%; $p=0.002$) (5, 120). The absence of these translocations correlated with the AA PCa disease. Thus, while the TMPRSS2:ERG fusion may help to diagnose PCa in EA patients, its low frequency in AA patients suggests that it neither helps to explain disease etiology nor aid with accurate diagnosis of aggressive disease in this group. In fact, this presents a problem for all patients who are fusion-negative, but it is particularly devastating for men of African ancestry.

Thus, dissecting the biological basis for TMPRSS2:ERG fusion-negative PCa represents an underexplored and clinically significant need for AA patients and has the potential to be exploited to define new diagnosis and treatment options. To meet this need, we have explored the role of miRNA-mediated mechanisms that drive disease in TMPRSS2 fusion-negative PCas. The rationale was that miRNAs act as alternative epigenetic drivers of PCa and allow precise stratification of patients. The goal was to develop a biological understanding of tumor drivers in AA men.

6. ARE miRNA RACE-SPECIFIC, EPIGENETIC DRIVERS FOR TMPRSS2 FUSION-NEGATIVE PCa?

Across and within races, the biological basis for TMPRSS2 fusion-negative tumors remains unexplored. Our recent findings and the work of others, however, suggests that epigenetic drivers are consequential in this form of PCa. There are racial differences in the methylome of AA and EA PCa patients (121-124). For example, AR, RAR β 2, and other genes have higher methylation prevalence in tumors of AA patients, whereas TIMP3 has higher methylation in non-involved normal AA prostate tissues (125). DNA methylation has also emerged as a regulator of expression for various miRNAs in the progression in PCa (126-128), but the extent of differential CpG methylation in AA and EA PCa remains under-explored.

There are global differences in the pattern of CpG DNA methylation in benign, cancerous, and metastatic samples in fusion-positive vs fusion-negative

PCas (129). Similarly, in a larger cohort, methylated DNA immunoprecipitation sequencing identified differential CpG methylation based on the TMPRSS2-ERG rearrangement status (130). These data suggest that DNA methylation events distort gene expression patterns in fusion-negative PCa and drive this disease. Although these events are significant across the genome, we have pursued the relationships between DNA methylation and miRNA expression for strategic reasons.

Together, these data support the concept that altered methylation of miRNA provides an alternative route for the initiation and progression of PCa in AA patients, whose tumors are commonly TMPSS2 fusion-negative. This raises the possibility that racially specific hypermethylation of key miRNAs drives alternative routes for the initiation and progression of PCa in AA patients, independent of TMPRSS2:ERG fusion.

7. AN ANALYTICAL PIPELINE TO EXAMINE CHANGES IN miRNA IN TMPSS2 FUSION-NEGATIVE PCa

To test this broad goal, we developed an integrative genomic pipeline to identify miRNAs that are associated with altered DNA methylation and TMPRSS2 fusion-negative PCas. We subsequently integrated our previous findings on miRNAs that are predictive of aggressive tumors and AA PCas (86, 87) and combined these findings (17, 131, 132) to identify, in fusion-negative PCa, which of these miRNAs is altered through DNA methylation (Figure 1).

Specifically, we performed analyses of differential expression of miRNA genes (DEG) in publically available data by mining two different PCa cohorts in TCGA: the main TCGA cohort of localized PCa (15) and the Memorial Sloan Kettering Cancer Center (MSKCC) cohort of 91 tumors (17). In the main cohort, we identified 48 miRNA DEG in altered fusion-negative vs -positive disease ($p_{\text{corrected}} < 0.005$) that also associated with reciprocal and CpG DNA methylation ($p_{\text{corrected}} < 0.005$).

In the MSKCC cohort, we identified miRNA DEG in fusion-negative vs -positive disease in smaller numbers of AA and EA patients. To this, we also combined miRNA expression associated with race. Huang *et al.* (133) evaluated differences in population-level expression in 757 miRNAs in HapMap lymphoblastoid cell lines derived from 53 CEU (Utah residents with northern and western European ancestry) and 54 YRI (Yoruba people from Ibadan, Nigeria). Of all miRNAs evaluated, and after stringent correction for multiple testing, 33 differed between these two ethnic groups, $p_{\text{corrected}} < 0.005$.

Finally, these miRNAs were filtered further to focus on miRNAs that we had established to be associated with disease progression, and with AA




Figure 1. An integrative pipeline to identify miRNA altered by DNA methylation in TMPRSS2 fusion negative PCa. Publicly available data from the main TCGA cohort tumors (15) and the Memorial Sloan Kettering Cancer Center (MSKCC) cohort of 91 tumors (17) was examined to identify miRNA that differentially expressed and associated with differential DNA methylation. Subsequently these miRNAs were examined for being differentially expressed between TMPRSS2 fusion positive and negative tumors, expression in lymphoblastoid cells from 53 CEU (Utah residents with northern and western European ancestry) and 54 YRI (Yoruba people from Ibadan, Nigeria) populations, and known from our previous studies to be associated with aggressive PCa, and enriched in AA PCa.

PCas identified in patient samples and cell lines from Roswell Park Cancer Institute (RPCI) (86) and Tuskegee University (TU) (87). This approach identified 18 miRNAs as associated with aggressive PCa. These are candidates to drive alternative progression pathways in fusion-negative PCas in AA and EA patients. Across these miRNAs, there was an inverse correlation between CpG methylation and expression of associated TMPRSS2 fusion-negative disease, thus providing proof-of-concept that the race-specific miRNAs are differentially expressed in TMPRSS2:ERG-negative tumors (Figure 2). Some of these miRNAs (e.g. miR-125b) have been investigated extensively in prostate tissue, whereas others have few, if any, publications related to PCa (Table 1). For example, miR-376b, which was initially identified from the TU cohort and verified in the YRI cohort to be ancestry-related, has a loss of methylated CpG islands in the promoter region in TMPRSS2:ERG-negative tumors compared to TMPRSS2:ERG-positive tumors; this pattern is seen for many of the miRNAs. miR-376b is associated with the

mTOR-related autophagy proteins, TG4C and BECN1, and relates to angiogenesis through regulation of the HIF1alpha VEGFA/Notch1 signaling pathway (134, 135).

8. DOWNSTREAM TARGETS OF KEY miRNA

For several of these miRNAs, we have also characterized known targets and suggest that there is convergence on regulators of the epigenome. For example, miR-125b targets Nuclear Receptor Corepressor 2/Silencing Mediator Of Retinoic Acid and Thyroid Hormone Receptor (NCOR2/SMRT) (136) and an interacting co-factor that governs CpG methylation dependent silencing, Zinc Finger And BTB Domain Containing 33 (ZBTB33/Kaiso), which targets miR-125a-5p, a member of the miR-125 family (137). Reflecting changes in miR-125b expression in patients who experience biochemical failure, we separately revealed, in a cohort of 172 PCa patients, that Kaiso is overexpressed in a cohort of AA PCa patients in the




Figure 2. Inverse relationships between CpG methylation and expression of 18 miRNAs associated with TMPRSS2 fusion-negative disease across 333 localized tumors in the TCGA cohort (15) ($p = -0.5.6$).

University of Alabama at Birmingham/TU cohort (138). As determined with another tissue microarray of 720 PCA patients from RPCI, NCOR2/SMRT expression also predicts progression risk. Similarly, miR-152 appears to regulate proteins involved in control of the epigenome. Ectopic expression of miR-152 results in decreased cellular proliferation, migration, and invasion, and decreased expression of DNMT1 through binding in the DNMT1 3'UTR (87) and thereby contributes to aberration of hypermethylation in AA tumors (87). Thus, our approaches support the concept that disease progression is influenced by miRNA in both EA and AA tumors and that increased aggressiveness of AA tumors may reflect both common and unique targetomes of mRNA networks. In particular, our studies have suggested that, within these targetomes, are mRNAs that encode for epigenetic regulators of DNA methylation and histone modifications. This suggests a complex interplay between upstream epigenetic regulation and downstream regulation of epigenetic regulators, which together determines disease risk.

In the AA PCa cohort of miRNAs, we have examined the impact of DNA methylation on some of the miRNAs. Validation of specific miRNAs by q-PCR across a panel of 11 cell lines demonstrated that miR-132, miR-367b, miR-410, and miR-152 were decreased in the more aggressive PCa cells, and expression of each miRNA was reversed after treatment of the cells with 5-aza-2'-deoxycytidine, suggesting a role for CpG methylation. Others have suggested that, in PCas, miR-132 is silenced by methylation (139). Our data confirm

that miR-152 is silenced by methylation in PCas (87). In a comparison of normal/tumor ratios of miR-152 expression in 20 EA and 20 AA PCa patients, miR-152 expression was decreased in tumors of 67% of all patients, with 50 % of the AA patients showing a difference, compared to only 35% of EA patients. We also found that miR-152 expression was lower in non-malignant tissues from AA patients compared to those of EAs, suggesting the presence of heritable differences in the control of miR-152 expression.

The impact of genetic variation on miRNA expression. In support of these heritable differences, three single nucleotide polymorphisms (SNPs) on chromosome 17 (rs1553754, rs11079828, and rs6504340) are associated with miR-152 expression at the genome-wide level, and differ in minor allele frequency by 28% on average in comparing the YRI and CEU populations (140, 141). In fact, the minor alleles at two of these SNPs for miRNA expression quantitative trait loci (miR-eQTL), rs1553754 and rs6504340, are different in the YRI and CEU populations. These differences in the frequency of alleles associated with miRNA expression are evidence that the difference in methylation rates in miR-152 could be driven by differences in genetic variation seen between African and European populations. In addition to this population-level evidence, through our work, we have identified rs12940701 (C/T) in miR152; the minor allele (T) has a relatively high frequency (26%) in the CEU population versus the YRI population (11%), suggesting that EAs have lower methylation rates due to the presence of a T nucleotide instead of a C nucleotide,

Table 1. Summary of miRNA associated with TMPRSS2 fusion-negative PCa and inversely correlated with DNA CpG methylation

miRNA	Family	Clustered	Serum Detected	Number of PCa pubs
Let-7c	Let-7	mir-99a	Y	9
miR-106a	Mir-17	mir-19b, mir-363	Y*	7
miR-125b1	Mir-10		Y	22
miR-152	Mir-148		Y	5
miR-17	Mir-17	mir-19b	Y*	17
miR-19b	Mir-19	mir-17	Y	2
miR-193b	Mir-193		Y	3
miR-197	Mir-197		Y	1
miR-29b1	Mir-29		Y	10
miR-200b	Mir-8	mir-429	Y	13
miR-30b	Mir-30		Y	1
miR-30c1	Mir-30		Y	5
miR-30c2	Mir-30		N	5
miR-363	Mir-363	mir106a, mir-19b	Y	1
miR-376b	Mir368		Y	-
miR-429	Mir-8	mir-200b	Y	1
miR-450	Mir-450		Y	-
miR-99a	Mir-10	Let-7c	Y	6
The 18 miRNAs represent 13 families, and several cluster < 10 kb from each other. A pilot study was undertaken to examine miRNA expression in the sera from 8 EA PCa patients and 7 AA PCa patients. 17 of 18 miRNAs were detectable in the sera and two were significantly different (*) between the two groups. Some of these miRNAs are well-described in PCas (e.g., miR-125b), whereas others are unexplored (e.g., miR-376b).				

which is less frequent in the Yoruba population. Indeed, the number of publications that demonstrate an increased rate of methylation in AAs compared to EAs is growing, supporting the value of these miRNAs as diagnostic for AA PCa.

9. PERSPECTIVES

There is an urgent need to identify and characterize minimally-invasive diagnostic markers of PCa progression in TMPRSS2:ERG fusion-negative AA patients, as these patients are generally underserved. By use of AA cell cultures and publicly available datasets, we have undertaken a discovery phase of interrogating miRNAs that associate with aggressive PCa. Several fundamental questions remain as to the impact of methylation on silencing of miRNA expression in PCas, particularly in AA patients. Thus, validation of the

capability of these miRNA serum biomarkers to predict aggressive PCa in AAs is required before these miRNAs can be considered for clinical application.

In preliminary studies, we have examined expression of these 18 miRNAs in the sera of EA and AA PCa patients with matched stage and grade of disease. In this pilot study, only one miRNA (miR-30c-5p) was undetected in PCa patient serum. Even within this small set of patients, however, several miRNAs were expressed at different levels in AA vs EA patients.

These findings suggest that epigenetic events affected by genetic variation differentially regulate miRNAs in AA PCa patients and are drivers of TMPRSS2:ERG-negative tumors. Identification of differentially methylated regions in AA and EA PCas will aid in defining a more personalized risk assessment of developing aggressive PCa, for not only AA men, but all men with TMPRSS2:ERG-negative tumors.

10. ACKNOWLEDGEMENTS

This work was supported by the Prostate Program of the Department of Defense Congressionally Directed Medical Research Programs (W81XWH-14-1-0608, W81XWH-11-2-0033 to MJC and PC120913 to CY). MJC and LESC acknowledge support, in part, of the National Cancer Institute Cancer Center Support Grant to the Roswell Park Cancer Institute (CA016056). CY also acknowledges support from the National Institute for Health, specifically G12 RR03059-21A1 (NIH/NIMHD), 1 R21 CA188799-01 (NIH/NCI), and U54 CA118623 (NIH/NCI).

11. REFERENCES

1. F. H. Schroder, J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Maattanen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning and A. Auvinen: Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med*, 360(13), 1320-8 (2009)
DOI: 10.1056/NEJMoa0810084
2. G. L. Andriole, E. D. Crawford, R. L. Grubb, 3rd, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O'Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan, C. D. Berg and P. P. Team: Mortality

- results from a randomized prostate-cancer screening trial. *N Engl J Med*, 360(13), 1310-9 (2009)
DOI: 10.1056/NEJMoa0810696
3. S. J. Freedland: Screening, risk assessment, and the approach to therapy in patients with prostate cancer. *Cancer*, 117(6), 1123-35 (2011)
DOI: 10.1002/cncr.25477
4. M. S. Cookson, G. Aus, A. L. Burnett, E. D. Canby-Hagino, A. V. D'Amico, R. R. Dmochowski, D. T. Eton, J. D. Forman, S. L. Goldenberg, J. Hernandez, C. S. Higano, S. R. Kraus, J. W. Moul, C. Tangen, J. B. Thrasher and I. Thompson: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. *The Journal of urology*, 177(2), 540-5 (2007)
DOI: 10.1016/j.juro.2006.10.097
5. K. Yamoah, C. Deville, N. Vapiwala, E. Spangler, C. M. Zeigler-Johnson, B. Malkowicz, D. I. Lee, M. Kattan, A. P. Dicker and T. R. Rebbeck: African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. *Urol Oncol*, 33(2), 70 e15-22 (2015)
6. M. S. Ludwig, D. A. Kuban, S. S. Strom, X. L. Du, D. S. Lopez and J. M. Yamal: Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. *Am J Mens Health* (2015)
7. J. Jones, W. Grizzle, H. Wang and C. Yates: MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans. *Biotech Histochem*, 88(7), 410-24 (2013)
DOI: 10.3109/10520295.2013.807069
8. I. J. Powell and A. Bollig-Fischer: Minireview: the molecular and genomic basis for prostate cancer health disparities. *Mol Endocrinol*, 27(6), 879-91 (2013)
DOI: 10.1210/me.2013-1039
9. B. F. Drake, T. E. Keane, C. M. Mosley, S. A. Adams, K. T. Elder, M. V. Modayil, J. R. Ureda and J. R. Hebert: Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. *J S C Med Assoc*, 102(7), 241-9 (2006)
10. K. A. Cooney: Hereditary prostate cancer in African-American families. *Semin Urol Oncol*, 16(4), 202-6 (1998)
11. P. E. Li and P. S. Nelson: Prostate cancer genomics. *Curr Urol Rep*, 2(1), 70-8 (2001)
DOI: 10.1007/s11934-001-0028-6
12. W. B. Isaacs: Molecular genetics of prostate cancer. *Cancer Surv*, 25, 357-79 (1995)
13. S. C. Baca, D. Prandi, M. S. Lawrence, J. M. Mosquera, A. Romanel, Y. Drier, K. Park, N. Kitabayashi, T. Y. MacDonald, M. Ghandi, E. Van Allen, G. V. Kryukov, A. Sboner, J. P. Theurillat, T. D. Soong, E. Nickerson, D. Auclair, A. Tewari, H. Beltran, R. C. Onofrio, G. Boysen, C. Guiducci, C. E. Barbieri, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, A. H. Ramos, W. Winckler, M. Cipicchio, K. Ardlie, P. W. Kantoff, M. F. Berger, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, O. Elemento, G. Getz, F. Demichelis, M. A. Rubin and L. A. Garraway: Punctuated evolution of prostate cancer genomes. *Cell*, 153(3), 666-77 (2013)
DOI: 10.1016/j.cell.2013.03.021
14. C. E. Barbieri, S. C. Baca, M. S. Lawrence, F. Demichelis, M. Blattner, J. P. Theurillat, T. A. White, P. Stojanov, E. Van Allen, N. Stransky, E. Nickerson, S. S. Chae, G. Boysen, D. Auclair, R. C. Onofrio, K. Park, N. Kitabayashi, T. Y. MacDonald, K. Sheikh, T. Vuong, C. Guiducci, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, W. M. Hussain, A. H. Ramos, W. Winckler, M. C. Redman, K. Ardlie, A. K. Tewari, J. M. Mosquera, N. Rupp, P. J. Wild, H. Moch, C. Morrissey, P. S. Nelson, P. W. Kantoff, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, G. Getz, M. A. Rubin and L. A. Garraway: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat Genet*, 44(6), 685-9 (2012)
DOI: 10.1038/ng.2279
15. s. c. m. o. Cancer Genome Atlas Research Network. Electronic address and N. Cancer Genome Atlas Research: The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, 163(4), 1011-25 (2015)

- DOI: 10.1016/j.cell.2015.10.025
16. C. E. Barbieri, S. C. Baca, M. S. Lawrence, F. Demichelis, M. Blattner, J. P. Theurillat, T. A. White, P. Stojanov, E. Van Allen, N. Stransky, E. Nickerson, S. S. Chae, G. Boysen, D. Auclair, R. C. Onofrio, K. Park, N. Kitabayashi, T. Y. MacDonald, K. Sheikh, T. Vuong, C. Guiducci, K. Cibulskis, A. Sivachenko, S. L. Carter, G. Saksena, D. Voet, W. M. Hussain, A. H. Ramos, W. Winckler, M. C. Redman, K. Ardlie, A. K. Tewari, J. M. Mosquera, N. Rupp, P. J. Wild, H. Moch, C. Morrissey, P. S. Nelson, P. W. Kantoff, S. B. Gabriel, T. R. Golub, M. Meyerson, E. S. Lander, G. Getz, M. A. Rubin and L. A. Garraway: Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nature genetics*, 44(6), 685-9 (2012)
DOI: 10.1038/ng.2279
17. B. S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, C. Sander, C. L. Sawyers and W. L. Gerald: Integrative genomic profiling of human prostate cancer. *Cancer Cell*, 18(1), 11-22 (2010)
DOI: 10.1016/j.ccr.2010.05.026
18. H. Hieronymus, N. Schultz, A. Gopalan, B. S. Carver, M. T. Chang, Y. Xiao, A. Heguy, K. Huberman, M. Bernstein, M. Assel, R. Murali, A. Vickers, P. T. Scardino, C. Sander, V. Reuter, B. S. Taylor and C. L. Sawyers: Copy number alteration burden predicts prostate cancer relapse. *Proc Natl Acad Sci U S A*, 111(30), 11139-44 (2014)
DOI: 10.1073/pnas.1411446111
19. G. Gundem, P. Van Loo, B. Kremeyer, L. B. Alexandrov, J. M. Tubio, E. Papaemmanuil, D. S. Brewer, H. M. Kallio, G. Hognas, M. Annala, K. Kivinummi, V. Goody, C. Latimer, S. O'Meara, K. J. Dawson, W. Isaacs, M. R. Emmert-Buck, M. Nykter, C. Foster, Z. Kote-Jarai, D. Easton, H. C. Whitaker, I. P. U. Group, D. E. Neal, C. S. Cooper, R. A. Eeles, T. Visakorpi, P. J. Campbell, U. McDermott, D. C. Wedge and G. S. Bova: The evolutionary history of lethal metastatic prostate cancer. *Nature*, 520(7547), 353-7 (2015)
DOI: 10.1038/nature14347
20. C. S. Cooper, R. Eeles, D. C. Wedge, P. Van Loo, G. Gundem, L. B. Alexandrov, B. Kremeyer, A. Butler, A. G. Lynch, N. Camacho, C. E. Massie, J. Kay, H. J. Luxton, S. Edwards, Z. Kote-Jarai, N. Dennis, S. Merson, D. Leongamornlert, J. Zamora, C. Corbishley, S. Thomas, S. Nik-Zainal, M. Ramakrishna, S. O'Meara, L. Matthews, J. Clark, R. Hurst, R. Mithen, R. G. Bristow, P. C. Boutros, M. Fraser, S. Cooke, K. Raine, D. Jones, A. Menzies, L. Stebbings, J. Hinton, J. Teague, S. McLaren, L. Mudie, C. Hardy, E. Anderson, O. Joseph, V. Goody, B. Robinson, M. Maddison, S. Gamble, C. Greenman, D. Berney, S. Hazell, N. Livni, I. P. Group, C. Fisher, C. Ogden, P. Kumar, A. Thompson, C. Woodhouse, D. Nicol, E. Mayer, T. Dudderidge, N. C. Shah, V. Gnanapragasam, T. Voet, P. Campbell, A. Futreal, D. Easton, A. Y. Warren, C. S. Foster, M. R. Stratton, H. C. Whitaker, U. McDermott, D. S. Brewer and D. E. Neal: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. *Nat Genet*, 47(4), 367-72 (2015)
DOI: 10.1038/ng.3221
21. J. Sandoval and M. Esteller: Cancer epigenomics: beyond genomics. *Curr Opin Genet Dev*, 22(1), 50-5 (2012)
DOI: 10.1016/j.gde.2012.02.008
22. R. Holliday: The inheritance of epigenetic defects. *Science*, 238(4824), 163-70 (1987)
DOI: 10.1126/science.3310230
23. F. Valdes-Mora and S. J. Clark: Prostate cancer epigenetic biomarkers: next-generation technologies. *Oncogene*, 34(13), 1609-18 (2015)
DOI: 10.1038/onc.2014.111
24. C. S. Cooper and C. S. Foster: Concepts of epigenetics in prostate cancer development. *Br J Cancer*, 100(2), 240-5 (2009)
DOI: 10.1038/sj.bjc.6604771
25. S. Venkatesh and J. L. Workman: Histone exchange, chromatin structure and the regulation of transcription. *Nat Rev Mol Cell Biol*, 16(3), 178-89 (2015)
DOI: 10.1038/nrm3941
26. K. K. Lee and J. L. Workman: Histone acetyltransferase complexes: one size doesn't fit all. *Nature reviews. Molecular cell biology*, 8(4), 284-95 (2007)
DOI: 10.1038/nrm2145

27. H. J. Kim and S. C. Bae: Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. *American journal of translational research*, 3(2), 166-79 (2011)
28. M. Albert and K. Helin: Histone methyltransferases in cancer. *Seminars in cell & developmental biology*, 21(2), 209-20 (2010)
DOI: 10.1016/j.semcdb.2009.10.007
29. S. M. Kooistra and K. Helin: Molecular mechanisms and potential functions of histone demethylases. *Nature reviews. Molecular cell biology*, 13(5), 297-311 (2012)
DOI: 10.1038/nrm3327
30. M. Esteller: Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat Rev Genet*, 8(4), 286-98 (2007)
DOI: 10.1038/nrg2005
31. M. J. Campbell and B. M. Turner: Altered histone modifications in cancer. *Advances in experimental medicine and biology*, 754, 81-107 (2013)
DOI: 10.1007/978-1-4419-9967-2_4
32. K. Chiam, C. Ricciardelli and T. Bianco-Miotto: Epigenetic biomarkers in prostate cancer: Current and future uses. *Cancer Lett* (2012)
33. C. Jeronimo, P. J. Bastian, A. Bjartell, G. M. Carbone, J. W. Catto, S. J. Clark, R. Henrique, W. G. Nelson and S. F. Shariat: Epigenetics in prostate cancer: biologic and clinical relevance. *Eur Urol*, 60(4), 753-66 (2011)
DOI: 10.1016/j.eururo.2011.06.035
34. M. M. Shen and C. Abate-Shen: Molecular genetics of prostate cancer: new prospects for old challenges. *Genes Dev*, 24(18), 1967-2000 (2010)
DOI: 10.1101/gad.1965810
35. S. Varambally, S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda, D. Ghosh, K. J. Pienta, R. G. Sewalt, A. P. Otte, M. A. Rubin and A. M. Chinnaiyan: The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature*, 419(6907), 624-9 (2002)
DOI: 10.1038/nature01075
36. O. R. Saramaki, T. L. Tammela, P. M. Martikainen, R. L. Vessella and T. Visakorpi: The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. *Genes Chromosomes Cancer*, 45(7), 639-45 (2006)
DOI: 10.1002/gcc.20327
37. H. Denis, M. N. Ndlovu and F. Fuks: Regulation of mammalian DNA methyltransferases: a route to new mechanisms. *EMBO reports*, 12(7), 647-56 (2011)
DOI: 10.1038/embor.2011.110
38. S. Djebali, C. A. Davis, A. Merkel, A. Dobin, T. Lassmann, A. Mortazavi, A. Tanzer, J. Lagarde, W. Lin, F. Schlesinger, C. Xue, G. K. Marinov, J. Khatun, B. A. Williams, C. Zaleski, J. Rozowsky, M. Roder, F. Kokocinski, R. F. Abdelhamid, T. Alioto, I. Antoshechkin, M. T. Baer, N. S. Bar, P. Batut, K. Bell, I. Bell, S. Chakraborty, X. Chen, J. Chrast, J. Curado, T. Derrien, J. Drenkow, E. Dumais, J. Dumais, R. Duttagupta, E. Falconnet, M. Fastuca, K. Fejes-Toth, P. Ferreira, S. Foissac, M. J. Fullwood, H. Gao, D. Gonzalez, A. Gordon, H. Gunawardena, C. Howald, S. Jha, R. Johnson, P. Kapranov, B. King, C. Kingswood, O. J. Luo, E. Park, K. Persaud, J. B. Preall, P. Ribeca, B. Risk, D. Robyr, M. Sammeth, L. Schaffer, L. H. See, A. Shahab, J. Skancke, A. M. Suzuki, H. Takahashi, H. Tilgner, D. Trout, N. Walters, H. Wang, J. Wrobel, Y. Yu, X. Ruan, Y. Hayashizaki, J. Harrow, M. Gerstein, T. Hubbard, A. Reymond, S. E. Antonarakis, G. Hannon, M. C. Giddings, Y. Ruan, B. Wold, P. Carninci, R. Guigo and T. R. Gingeras: Landscape of transcription in human cells. *Nature*, 489(7414), 101-8 (2012)
DOI: 10.1038/nature11233
39. B. P. Lewis, C. B. Burge and D. P. Bartel: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell*, 120(1), 15-20 (2005)
DOI: 10.1016/j.cell.2004.12.035
40. M. V. Iorio and C. M. Croce: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO molecular medicine*, 4(3), 143-59 (2012)
DOI: 10.1002/emmm.201100209
41. J. Manikandan, J. J. Aarthi, S. D. Kumar and P. N. Pushparaj: Oncomirs: the potential role of non-coding microRNAs in understanding cancer. *Bioinformation*, 2(8), 330-4 (2008)
DOI: 10.6026/97320630002330

42. A. Esquela-Kerscher and F. J. Slack: Oncomirs - microRNAs with a role in cancer. *Nature reviews. Cancer*, 6(4), 259-69 (2006)
DOI: 10.1038/nrc1840
43. S. Volinia, G. A. Calin, C. G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R. L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C. C. Harris and C. M. Croce: A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci U S A*, 103(7), 2257-61 (2006)
DOI: 10.1073/pnas.0510565103
44. J. Lu, G. Getz, E. A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-Cordero, B. L. Ebert, R. H. Mak, A. A. Ferrando, J. R. Downing, T. Jacks, H. R. Horvitz and T. R. Golub: MicroRNA expression profiles classify human cancers. *Nature*, 435(7043), 834-8 (2005)
DOI: 10.1038/nature03702
45. T. Sun, Q. Wang, S. Balk, M. Brown, G. S. Lee and P. Kantoff: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. *Cancer Res*, 69(8), 3356-63 (2009)
DOI: 10.1158/0008-5472.CAN-08-4112
46. R. Medina, S. K. Zaidi, C. G. Liu, J. L. Stein, A. J. van Wijnen, C. M. Croce and G. S. Stein: MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. *Cancer research*, 68(8), 2773-80 (2008)
DOI: 10.1158/0008-5472.CAN-07-6754
47. N. Mercatelli, V. Coppola, D. Bonci, F. Miele, A. Costantini, M. Guadagnoli, E. Bonanno, G. Muto, G. V. Frajese, R. De Maria, L. G. Spagnoli, M. G. Farace and S. A. Ciafre: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. *PLoS ONE*, 3(12), e4029 (2008)
DOI: 10.1371/journal.pone.0004029
48. L. Wang, H. Tang, V. Thayanithy, S. Subramanian, A. L. Oberg, J. M. Cunningham, J. R. Cerhan, C. J. Steer and S. N. Thibodeau: Gene networks and microRNAs implicated in aggressive prostate cancer. *Cancer research*, 69(24), 9490-7 (2009)
DOI: 10.1158/0008-5472.CAN-09-2183
49. J. Hao, C. Zhang, A. Zhang, K. Wang, Z. Jia, G. Wang, L. Han, C. Kang and P. Pu: miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. *Oncol Rep*, 27(5), 1504-10 (2012)
50. P. Tucci, M. Agostini, F. Grespi, E. K. Markert, A. Terrinoni, K. H. Vousden, P. A. Muller, V. Dotsch, S. Kehrloesser, B. S. Sayan, G. Giaccone, S. W. Lowe, N. Takahashi, P. Vandenabeele, R. A. Knight, A. J. Levine and G. Melino: Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, 109(38), 15312-7 (2012)
DOI: 10.1073/pnas.1110977109
51. J. J. Zhao, J. Lin, H. Yang, W. Kong, L. He, X. Ma, D. Coppola and J. Q. Cheng: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. *J Biol Chem*, 283(45), 31079-86 (2008)
DOI: 10.1074/jbc.M806041200
52. T. E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C. L. Shapiro, S. Jacob and S. Majumder: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J Biol Chem*, 283(44), 29897-903 (2008)
DOI: 10.1074/jbc.M804612200
53. D. Lin, F. Cui, Q. Bu and C. Yan: The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. *J Int Med Res*, 39(5), 1870-5 (2011)
DOI: 10.1177/147323001103900530
54. S. Wach, E. Nolte, J. Szczyrba, R. Stohr, A. Hartmann, T. Orntoft, L. Dyrskjot, E. Eltze, W. Wieland, B. Keck, A. B. Ekici, F. Grasser and B. Wullich: MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. *International journal of cancer. Journal international du cancer*, 130(3), 611-21 (2012)
DOI: 10.1002/ijc.26064
55. P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanian, A. Peterson, J. Noteboom, K. C. O'Briant, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin and M. Tewari: Circulating microRNAs

- as stable blood-based markers for cancer detection. *Proceedings of the National Academy of Sciences of the United States of America*, 105(30), 10513-8 (2008)
DOI: 10.1073/pnas.0804549105
56. P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanian, A. Peterson, J. Noteboom, K. C. O'Brian, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin and M. Tewari: Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci U S A*, 105(30), 10513-8 (2008)
DOI: 10.1073/pnas.0804549105
57. A. W. Tong, P. Fulgham, C. Jay, P. Chen, I. Khalil, S. Liu, N. Senzer, A. C. Eklund, J. Han and J. Nemunaitis: MicroRNA profile analysis of human prostate cancers. *Cancer Gene Ther*, 16(3), 206-16 (2009)
58. M. Ozen, C. J. Creighton, M. Ozdemir and M. Ittmann: Widespread deregulation of microRNA expression in human prostate cancer. *Oncogene*, 27(12), 1788-93 (2008)
DOI: 10.1038/sj.onc.1210809
59. K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. Tammela and T. Visakorpi: MicroRNA expression profiling in prostate cancer. *Cancer research*, 67(13), 6130-5 (2007)
DOI: 10.1158/0008-5472.CAN-07-0533
60. Y. S. Lee, H. K. Kim, S. Chung, K. S. Kim and A. Dutta: Depletion of human microRNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. *J Biol Chem*, 280(17), 16635-41 (2005)
DOI: 10.1074/jbc.M412247200
61. X. B. Shi, L. Xue, J. Yang, A. H. Ma, J. Zhao, M. Xu, C. G. Tepper, C. P. Evans, H. J. Kung and R. W. deVere White: An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. *Proc Natl Acad Sci U S A*, 104(50), 19983-8 (2007)
DOI: 10.1073/pnas.0706641104
62. X. Peng, W. Guo, T. Liu, X. Wang, X. Tu, D. Xiong, S. Chen, Y. Lai, H. Du, G. Chen, G. Liu, Y. Tang, S. Huang and X. Zou: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. *PLoS One*, 6(5), e20341 (2011)
DOI: 10.1371/journal.pone.0020341
63. D. Kong, Y. Li, Z. Wang, S. Banerjee, A. Ahmad, H. R. Kim and F. H. Sarkar: miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. *Stem Cells*, 27(8), 1712-21 (2009)
DOI: 10.1002/stem.101
64. P. A. Gregory, A. G. Bert, E. L. Paterson, S. C. Barry, A. Tsykin, G. Farshid, M. A. Vadas, Y. Khew-Goodall and G. J. Goodall: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nature cell biology*, 10(5), 593-601 (2008)
DOI: 10.1038/ncb1722
65. M. A. Cortez, C. Bueso-Ramos, J. Ferdin, G. Lopez-Berestein, A. K. Sood and G. A. Calin: MicroRNAs in body fluids-the mix of hormones and biomarkers. *Nature reviews. Clinical oncology*, 8(8), 467-77 (2011)
DOI: 10.1038/nrclinonc.2011.76
66. A. Goyal, G. H. Delves, M. Chopra, B. A. Lwaleed and A. J. Cooper: Prostate cells exposed to lycopene *in vitro* liberate lycopene-enriched exosomes. *BJU Int*, 98(4), 907-11 (2006)
DOI: 10.1111/j.1464-410X.2006.06434.x
67. D. D. Taylor and C. Gercel-Taylor: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol*, 110(1), 13-21 (2008)
DOI: 10.1016/j.ygyno.2008.04.033
68. H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J. J. Lee and J. O. Lotvall: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*, 9(6), 654-9 (2007)
DOI: 10.1038/ncb1596
69. T. El-Hefnawy, S. Raja, L. Kelly, W. L. Bigbee, J. M. Kirkwood, J. D. Luketich and T. E. Godfrey: Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. *Clin Chem*, 50(3), 564-73 (2004)
DOI: 10.1373/clinchem.2003.028506
70. X. Chen, Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang,

- J. Guo, Y. Zhang, J. Chen, X. Guo, Q. Li, X. Li, W. Wang, J. Wang, X. Jiang, Y. Xiang, C. Xu, P. Zheng, J. Zhang, R. Li, H. Zhang, X. Shang, T. Gong, G. Ning, K. Zen and C. Y. Zhang: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res*, 18(10), 997-1006 (2008)
DOI: 10.1038/cr.2008.282
71. C. G. Liu, G. A. Calin, S. Volinia and C. M. Croce: MicroRNA expression profiling using microarrays. *Nat Protoc*, 3(4), 563-78 (2008)
DOI: 10.1038/nprot.2008.14
72. G. Rabinowits, C. Gercel-Taylor, J. M. Day, D. D. Taylor and G. H. Kloecker: Exosomal microRNA: a diagnostic marker for lung cancer. *Clin Lung Cancer*, 10(1), 42-6 (2009)
DOI: 10.3816/CLC.2009.n.006
73. K. R. Leite, A. Tomiyama, S. T. Reis, J. M. Sousa-Canavez, A. Sanudo, M. F. Dall'oglio, L. H. Camara-Lopes and M. Srougi: MicroRNA-100 Expression is Independently Related to Biochemical Recurrence of Prostate Cancer. *J Urol*, 185(3), 1118-22 (2011)
DOI: 10.1016/j.juro.2010.10.035
74. M. D. Mattie, C. C. Benz, J. Bowers, K. Sensinger, L. Wong, G. K. Scott, V. Fedele, D. Ginzinger, R. Getts and C. Haqq: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. *Mol Cancer*, 5, 24 (2006)
DOI: 10.1186/1476-4598-5-24
75. K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. Tammela and T. Visakorpi: MicroRNA expression profiling in prostate cancer. *Cancer Res*, 67(13), 6130-5 (2007)
doi:67/13/6130 (pii) 10.1158/0008-5472.CAN-07-0533
76. L. Wang, H. Tang, V. Thayanithy, S. Subramanian, A. L. Oberg, J. M. Cunningham, J. R. Cerhan, C. J. Steer and S. N. Thibodeau: Gene networks and microRNAs implicated in aggressive prostate cancer. *Cancer Res*, 69(24), 9490-7 (2009)
DOI: 10.1158/0008-5472.CAN-09-2183
77. E. S. Martens-Uzunova, S. E. Jalava, N. F. Dits, G. J. van Leenders, S. Moller, J. Trapman, C. H. Bangma, T. Litman, T. Visakorpi and G. Jenster: Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. *Oncogene* 31(8):978-91 (2011)
DOI: 10.1038/onc.2011.304
78. A. L. Kasinski and F. J. Slack: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. *Nature reviews. Cancer*, 11(12), 849-64 (2011)
DOI: 10.1038/nrc3166
79. P. Gandellini, M. Folini, N. Longoni, M. Pennati, M. Binda, M. Colecchia, R. Salvioni, R. Supino, R. Moretti, P. Limonta, R. Valdagni, M. G. Daidone and N. Zaffaroni: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. *Cancer Res*, 69(6), 2287-95 (2009)
DOI: 10.1158/0008-5472.CAN-08-2894
80. Y. Li, T. G. VandenBoom, 2nd, D. Kong, Z. Wang, S. Ali, P. A. Philip and F. H. Sarkar: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. *Cancer Res*, 69(16), 6704-12 (2009)
DOI: 10.1158/0008-5472.CAN-09-1298
81. D. Lodygin, V. Tarasov, A. Epanchintsev, C. Berking, T. Knyazeva, H. Korner, P. Knyazev, J. Diebold and H. Hermeking: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. *Cell Cycle*, 7(16), 2591-600 (2008)
DOI: 10.4161/cc.7.16.6533
82. H. Hermeking: The miR-34 family in cancer and apoptosis. *Cell Death Differ*, 17(2), 193-9
DOI: 10.1038/cdd.2009.56
83. I. Casanova-Salas, J. Rubio-Briones, A. Fernandez-Serra and J. A. Lopez-Guerrero: miRNAs as biomarkers in prostate cancer. *Clin Transl Oncol*, 14(11), 803-11 (2012)
DOI: 10.1007/s12094-012-0877-0
84. H. L. Zhang, L. F. Yang, Y. Zhu, X. D. Yao, S. L. Zhang, B. Dai, Y. P. Zhu, Y. J. Shen, G. H. Shi and D. W. Ye: Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. *Prostate*, 71(3), 326-31 (2011)
DOI: 10.1002/pros.21246
85. J. C. Brase, M. Johannes, T. Schlomm, M.

- Falth, A. Haese, T. Steuber, T. Beissbarth, R. Kuner and H. Sultmann: Circulating miRNAs are correlated with tumor progression in prostate cancer. *Int J Cancer*, 128(3), 608-16 (2011)
DOI: 10.1002/ijc.25376
86. P. K. Singh, L. Preus, Q. Hu, L. Yan, M. D. Long, C. D. Morrison, M. Nesline, C. S. Johnson, S. Koochekpour, M. Kohli, S. Liu, D. L. Trump, L. E. Sucheston-Campbell and M. J. Campbell: Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. *Oncotarget*, 5(3), 824-40 (2014)
DOI: 10.18632/oncotarget.1776
87. S. C. Theodore, M. Davis, F. Zhao, H. Wang, D. Chen, J. Rhim, W. Dean-Colomb, T. Turner, W. Ji, G. Zeng, W. Grizzle and C. Yates: MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltransferase 1. *Oncotarget*, 5(11), 3512-25 (2014)
DOI: 10.18632/oncotarget.1953
88. Y. A. Lussier, W. M. Stadler and J. L. Chen: Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. *J Am Med Inform Assoc*, 19(2), 156-60 (2012)
DOI: 10.1136/amiajnl-2011-000419
89. S. A. Tomlins, J. R. Day, R. J. Lonigro, D. H. Hovelson, J. Siddiqui, L. P. Kunju, R. L. Dunn, S. Meyer, P. Hodge, J. Groskopf, J. T. Wei and A. M. Chinnaiyan: Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. *Eur Urol* (2015) pii: S0302-2838(15)00397-8.
90. A. Young, N. Palanisamy, J. Siddiqui, D. P. Wood, J. T. Wei, A. M. Chinnaiyan, L. P. Kunju and S. A. Tomlins: Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. *Am J Clin Pathol*, 138(5), 685-96 (2012)
DOI: 10.1309/AJCPU7PPWUPY8OH
91. J. Yu, J. Yu, R. S. Mani, Q. Cao, C. J. Brenner, X. Cao, X. Wang, L. Wu, J. Li, M. Hu, Y. Gong, H. Cheng, B. Laxman, A. Vellaichamy, S. Shankar, Y. Li, S. M. Dhanasekaran, R. Morey, T. Barrette, R. J. Lonigro, S. A. Tomlins, S. Varambally, Z. S. Qin and A. M. Chinnaiyan: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. *Cancer Cell*, 17(5), 443-54 (2010)
DOI: 10.1016/j.ccr.2010.03.018
92. B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, R. J. Lonigro, A. Tsodikov, J. T. Wei, S. A. Tomlins and A. M. Chinnaiyan: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. *Cancer Res*, 68(3), 645-9 (2008)
DOI: 10.1158/0008-5472.CAN-07-3224
93. F. Demichelis, K. Fall, S. Perner, O. Andren, F. Schmidt, S. R. Setlur, Y. Hoshida, J. M. Mosquera, Y. Pawitan, C. Lee, H. O. Adami, L. A. Mucci, P. W. Kantoff, S. O. Andersson, A. M. Chinnaiyan, J. E. Johansson and M. A. Rubin: TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. *Oncogene*, 26(31), 4596-9 (2007)
DOI: 10.1038/sj.onc.1210237
94. S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X. W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J. E. Montie, R. B. Shah, K. J. Pienta, M. A. Rubin and A. M. Chinnaiyan: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science*, 310(5748), 644-8 (2005)
DOI: 10.1126/science.1117679
95. M. H. Vaarala, K. Porvari, A. Kyllonen, O. Lukkarienen and P. Vihko: The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. *Int J Cancer*, 94(5), 705-10 (2001)
DOI: 10.1002/ijc.1526
96. J. M. Lubieniecka, M. K. Cheteri, J. L. Stanford and E. A. Ostrander: Met160Val polymorphism in the TRMPSS2 gene and risk of prostate cancer in a population-based case-control study. *Prostate*, 59(4), 357-9 (2004)
DOI: 10.1002/pros.20005
97. J. Farrell, D. Young, Y. Chen, J. Cullen, I. L. Rosner, J. Kagan, S. Srivastava, L. D. Mc, I. A. Sesterhenn, S. Srivastava and G. Petrovics: Predominance of ERG-negative high-grade prostate cancers in African American men. *Mol Clin Oncol*, 2(6), 982-986 (2014)
DOI: 10.3892/mco.2014.378
98. J. St John, K. Powell, M. K. Conley-Lacomb

- and S. R. Chinni: TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. *J Cancer Sci Ther*, 4(4), 94-101 (2012)
DOI: 10.4172/1948-5956.1000119
99. W. Ma, K. Diep, H. A. Fritsche, N. Shore and M. Albitar: Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers. *Genet Test Mol Biomarkers*, 18(3), 156-63 (2014)
DOI: 10.1089/gtmb.2013.0424
100. S. Dijkstra, I. L. Birker, F. P. Smit, G. H. Leyten, T. M. de Reijke, I. M. van Oort, P. F. Mulders, S. A. Jannink and J. A. Schalken: Prostate cancer biomarker profiles in urinary sediments and exosomes. *J Urol*, 191(4), 1132-8 (2014)
DOI: 10.1016/j.juro.2013.11.001
101. D. W. Lin, L. F. Newcomb, E. C. Brown, J. D. Brooks, P. R. Carroll, Z. Feng, M. E. Gleave, R. S. Lance, M. G. Sanda, I. M. Thompson, J. T. Wei, P. S. Nelson and I. Canary Prostate Active Surveillance Study: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. *Clin Cancer Res*, 19(9), 2442-50 (2013)
DOI: 10.1158/1078-0432.CCR-12-3283
102. K. Park, J. T. Dalton, R. Narayanan, C. E. Barbieri, M. L. Hancock, D. G. Bostwick, M. S. Steiner and M. A. Rubin: TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. *J Clin Oncol*, 32(3), 206-11 (2014)
DOI: 10.1200/JCO.2013.49.8386
103. O. M. Casey, L. Fang, P. G. Hynes, W. G. Abou-Kheir, P. L. Martin, H. S. Tillman, G. Petrovics, H. O. Awwad, Y. Ward, R. Lake, L. Zhang and K. Kelly: TMPRSS2- driven ERG expression *in vivo* increases self-renewal and maintains expression in a castration resistant subpopulation. *PLoS One*, 7(7), e41668 (2012)
DOI: 10.1371/journal.pone.0041668
104. S. R. Williamson, S. Zhang, J. L. Yao, J. Huang, A. Lopez-Beltran, S. Shen, A. O. Osunkoya, G. T. MacLennan, R. Montironi and L. Cheng: ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. *Mod Pathol*, 24(8), 1120-7 (2011)
DOI: 10.1038/modpathol.2011.56
105. Y. Li, D. Kong, Z. Wang, A. Ahmad, B. Bao, S. Padhye and F. H. Sarkar: Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. *Cancer Prev Res (Phila)*, 4(9), 1495-506 (2011)
DOI: 10.1158/1940-6207.CAPR-11-0077
106. J. C. Brase, M. Johannes, H. Mannsperger, M. Falth, J. Metzger, L. A. Kacprzyk, T. Andrasiuk, S. Gade, M. Meister, H. Sirma, G. Sauter, R. Simon, T. Schlomm, T. Beissbarth, U. Korf, R. Kuner and H. Sultmann: TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. *BMC Cancer*, 11, 507 (2011)
DOI: 10.1186/1471-2407-11-507
107. J. Rubio-Briones, A. Fernandez-Serra, A. Calatrava, Z. Garcia-Casado, L. Rubio, M. A. Bonillo, I. Iborra, E. Solsona and J. A. Lopez-Guerrero: Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. *J Urol*, 183(5), 2054-61 (2010)
DOI: 10.1016/j.juro.2009.12.096
108. O. R. Saramaki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L. Tammela and T. Visakorpi: TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. *Clin Cancer Res*, 14(11), 3395-400 (2008)
DOI: 10.1158/1078-0432.CCR-07-2051
109. C. Magi-Galluzzi, T. Tsusuki, P. Elson, K. Simmerman, C. LaFargue, R. Esgueva, E. Klein, M. A. Rubin and M. Zhou: TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. *Prostate*, 71(5), 489-97 (2011)
DOI: 10.1002/pros.21265
110. M. Taris, J. Irani, P. Blanchet, L. Multigner, X. Cathelineau and G. Fromont: ERG expression in prostate cancer: the prognostic paradox. *Prostate*, 74(15), 1481-7 (2014)
DOI: 10.1002/pros.22863
111. S. Rawal, D. Young, M. Williams, M. Colombo, R. Krishnappa, G. Petrovics, D. G. McLeod,

- S. Srivastava and I. A. Sesterhenn: Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. *J Cancer*, 4(6), 468-72 (2013)
DOI: 10.7150/jca.6568
112. C. Magi-Galluzzi, T. Tsusuki, P. Elson, K. Simmerman, C. LaFargue, R. Esgueva, E. Klein, M. A. Rubin and M. Zhou: TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. *Prostate*, 71(5), 489-97 (2011)
DOI: 10.1002/pros.21265
113. V. N. Giri, K. Ruth, L. Hughes, R. G. Uzzo, D. Y. Chen, S. A. Boorjian, R. Viterbo and T. R. Rebbeck: Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. *BJU Int*, 107(3), 466-70 (2011)
DOI: 10.1111/j.1464-410X.2010.09522.x
114. M. Braun, D. Goltz, Z. Shaikhibrahim, W. Vogel, D. Bohm, V. Scheble, K. Sotlar, F. Fend, S. H. Tan, A. Dobi, G. Kristiansen, N. Wernert and S. Perner: ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies. *Prostate Cancer Prostatic Dis*, 15(2), 165-9 (2012)
DOI: 10.1038/pcan.2011.67
115. P. Rosen, I. A. Sesterhenn, S. A. Brassell, D. G. McLeod, S. Srivastava and A. Dobi: Clinical potential of the ERG oncoprotein in prostate cancer. *Nat Rev Urol*, 9(3), 131-7 (2012)
DOI: 10.1038/nrurol.2012.10
116. S. M. Falzarano, M. Zhou, P. Carver, T. Tsuzuki, K. Simmerman, H. He and C. Magi-Galluzzi: ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. *Virchows Arch*, 459(4), 441-7 (2011)
DOI: 10.1007/s00428-011-1128-4
117. J. Farrell, G. Petrovics, D. G. McLeod and S. Srivastava: Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. *Int J Mol Sci*, 14(8), 15510-31 (2013)
DOI: 10.3390/ijms140815510
118. P. Rosen, D. Pfister, D. Young, G. Petrovics, Y. Chen, J. Cullen, D. Bohm, S. Perner, A. Dobi, D. G. McLeod, I. A. Sesterhenn and S. Srivastava: Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. *Urology*, 80(4), 749-53 (2012)
DOI: 10.1016/j.urology.2012.07.001
119. K. R. Rice, Y. Chen, A. Ali, E. J. Whitman, A. Blase, M. Ibrahim, S. Elsamanoudi, S. Brassell, B. Furusato, N. Stingle, I. A. Sesterhenn, G. Petrovics, S. Miick, H. Rittenhouse, J. Groskopf, D. G. McLeod and S. Srivastava: Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. *Clin Cancer Res*, 16(5), 1572-6 (2010)
DOI: 10.1158/1078-0432.CCR-09-2191
120. K. Yamoah, M. H. Johnson, V. Choeurng, F. A. Faisal, K. Yousefi, Z. Haddad, A. E. Ross, M. Alshalafa, R. Den, P. Lal, M. Feldman, A. P. Dicker, E. A. Klein, E. Davicioni, T. R. Rebbeck and E. M. Schaeffer: Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. *J Clin Oncol*, 33(25), 2789-96 (2015)
DOI: 10.1200/JCO.2014.59.8912
121. D. N. Martin, A. M. Starks and S. Ambis: Biological determinants of health disparities in prostate cancer. *Current opinion in oncology*, 25(3), 235-41 (2013)
DOI: 10.1097/cco.0b013e32835eb5d1
122. B. Kwabi-Addo, S. Wang, W. Chung, J. Jelinek, S. R. Patierno, B. D. Wang, R. Andrawis, N. H. Lee, V. Apprey, J. P. Issa and M. Ittmann: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. *Clinical cancer research: an official journal of the American Association for Cancer Research*, 16(14), 3539-47 (2010)
DOI: 10.1158/1078-0432.CCR-09-3342
123. H. Enokida, H. Shiina, S. Urakami, M. Igawa, T. Ogishima, D. Pookot, L. C. Li, Z. L. Tabatabai, M. Kawahara, M. Nakagawa, C. J. Kane, P. R. Carroll and R. Dahiya: Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. *International journal of cancer. Journal international du cancer*, 116(2), 174-81 (2005)
DOI: 10.1002/ijc.21017
124. K. Woodson, R. Hayes, L. Wideroff, L. Villaruz

- and J. Tangrea: Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. *Prostate*, 55(3), 199-205 (2003)
DOI: 10.1002/pros.10236
125. B. Kwabi-Addo, S. Wang, W. Chung, J. Jelinek, S. R. Patierno, B. D. Wang, R. Andrawis, N. H. Lee, V. Apprey, J. P. Issa and M. Ittmann: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. *Clin Cancer Res*, 16(14), 3539-47 (2010)
DOI: 10.1158/1078-0432.CCR-09-3342
126. Y. Kobayashi, D. M. Absher, Z. G. Gulzar, S. R. Young, J. K. McKenney, D. M. Peehl, J. D. Brooks, R. M. Myers and G. Sherlock: DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. *Genome Res*, 21(7), 1017-27 (2011)
DOI: 10.1101/gr.119487.110
127. P. Lopez-Serra and M. Esteller: DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. *Oncogene*, 31(13), 1609-22 (2012)
DOI: 10.1038/onc.2011.354
128. A. Yaqinuddin, S. A. Qureshi, R. Qazi, S. Farooq and F. Abbas: DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness. *J Urol*, 182(2), 756-61 (2009)
DOI: 10.1016/j.juro.2009.03.082
129. V. T. Ho, M. Vanneman, H. Kim, T. Sasada, Y. J. Kang, M. Pasek, C. Cutler, J. Koreth, E. Alyea, S. Sarantopoulos, J. H. Antin, J. Ritz, C. Canning, J. Kutok, M. C. Mihm, G. Dranoff and R. Soiffer: Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. *Proc Natl Acad Sci U S A*, 106(37), 15825-30 (2009)
DOI: 10.1073/pnas.0908358106
130. S. T. Borno, A. Fischer, M. Kerick, M. Falth, M. Laible, J. C. Brase, R. Kuner, A. Dahl, C. Grimm, B. Sayanjali, M. Isau, C. Rohr, A. Wunderlich, B. Timmermann, R. Claus, C. Plass, M. Graefen, R. Simon, F. Demichelis, M. A. Rubin, G. Sauter, T. Schlomm, H. Sultmann, H. Lehrach and M. R. Schweiger: Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. *Cancer Discov*, 2(11), 1024-35 (2012)
DOI: 10.1158/2159-8290.CD-12-0041
131. C. Zhan, L. Yan, L. Wang, W. Jiang, Y. Zhang, J. Xi, L. Chen, Y. Jin, Y. Qiao, Y. Shi and Q. Wang: Identification of reference miRNAs in human tumors by TCGA miRNA-seq data. *Biochem Biophys Res Commun*, 453(3), 375-8 (2014)
DOI: 10.1016/j.bbrc.2014.09.086
132. M. S. Cline, B. Craft, T. Swatloski, M. Goldman, S. Ma, D. Haussler and J. Zhu: Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. *Sci Rep*, 3, 2652 (2013)
DOI: 10.1038/srep02652
133. R. S. Huang, E. R. Gamazon, D. Ziliak, Y. Wen, H. K. Im, W. Zhang, C. Wing, S. Duan, W. K. Bleibel, N. J. Cox and M. E. Dolan: Population differences in microRNA expression and biological implications. *RNA biology*, 8(4), 692-701 (2011)
DOI: 10.4161/rna.8.4.16029
134. G. Korkmaz, C. le Sage, K. A. Tekirdag, R. Agami and D. Gozuacik: miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1. *Autophagy*, 8(2), 165-76 (2012)
DOI: 10.4161/auto.8.2.18351
135. L. J. Li, Q. Huang, N. Zhang, G. B. Wang and Y. H. Liu: miR-376b-5p regulates angiogenesis in cerebral ischemia. *Mol Med Rep*, 10(1), 527-35 (2014)
DOI: 10.3892/mmr.2014.2172
136. X. Yang, L. Bemis, L. J. Su, D. Gao and T. W. Flaig: miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. *BioResearch open access*, 1(2), 55-62 (2012)
DOI: 10.1089/biores.2012.9903
137. H. Wang, W. Liu, S. Black, O. Turner, J. M. Daniel, W. Dean-Colomb, Q. P. He, M. Davis and C. Yates: Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression. *Oncotarget* (2015)
138. J. Jones, H. Wang, J. Zhou, S. Hardy, T. Turner, D. Austin, Q. He, A. Wells, W. E. Grizzle and C. Yates: Nuclear Kaiso indicates aggressive

prostate cancers and promotes migration and invasiveness of prostate cancer cells. *Am J Pathol*, 181(5), 1836-46 (2012)
DOI: 10.1016/j.ajpath.2012.08.008

139. A. Formosa, A. M. Lena, E. K. Markert, S. Cortelli, R. Miano, A. Mauriello, N. Croce, J. Vandesompele, P. Mestdagh, E. Finazzi-Agro, A. J. Levine, G. Melino, S. Bernardini and E. Candi: DNA methylation silences miR-132 in prostate cancer. *Oncogene*, 32(1), 127-34 (2013)
DOI: 10.1038/onc.2012.14
140. T. Huan, J. Rong, C. Liu, X. Zhang, K. Tanriverdi, R. Joehanes, B. H. Chen, J. M. Murabito, C. Yao, P. Courchesne, P. J. Munson, C. J. O'Donnell, N. Cox, A. D. Johnson, M. G. Larson, D. Levy and J. E. Freedman: Genome-wide identification of microRNA expression quantitative trait loci. *Nat Commun*, 6, 6601 (2015)
DOI: 10.1038/ncomms7601
141. M. J. Machiela and S. J. Chanock: LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics*, 31(21), 3555-7 (2015)
DOI: 10.1093/bioinformatics/btv402

Key Words: miRNA, DNA Methylation, TMPRSS2:ERG, Prostate Cancer, African American, Review

Send correspondence to: Moray J, Campbell, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263
Tel: 716 845-3037, E-mail: moray.campbell@roswellpark.org